Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.43 |
| ▸ | ESR1 | P03372 | 4/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA3 | P07451 | 3/20 | 0.41 |
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | CA6 | P23280 | 3/20 | 0.41 |
| ▸ | CA5A | P35218 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nyasol SCHEMBL8416158 | 1.00 | APP (0.43) | APPESR1ESR2MAOBAKR1B1 | |
| Nyasol SCHEMBL776218 | 1.00 | APP (0.43) | APPESR1ESR2MAOBAKR1B1 | |
| Nyasol SCHEMBL799383 | 1.00 | APP (0.43) | APPESR1ESR2MAOBAKR1B1 | |
| Nyasol SCHEMBL30712027 | 1.00 | APP (0.43) | APPESR1ESR2MAOBAKR1B1 | |
| SCHEMBL13558420 | 0.92 | CYP3A4 (0.46) | APPESR1ESR2MAOBAKR1B1 | |
| SCHEMBL7861271 | 0.92 | CYP3A4 (0.46) | APPESR1ESR2MAOBAKR1B1 | |
| SCHEMBL799612 | 0.90 | MAOB (0.39) | APPESR1ESR2MAOBAKR1B1 | |
| SCHEMBL805124 | 0.87 | MAPT (0.50) | ESR2PTGS2KDM4EALDH1A1MAPT | |
| SCHEMBL7861615 | 0.87 | MAPT (0.50) | ESR2PTGS2KDM4EALDH1A1MAPT | |
| SCHEMBL7864584 | 0.87 | MAPT (0.50) | ESR2PTGS2KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195452-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. | 2025-06-19 | — | — | US | claimed |
| EP-4561582-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | Iaterion, Inc. (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024026037-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. (US) | 2024-02-01 | — | — | WO | claimed |
| US-20120277169-A1 | NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES | BIONOVO, INC. (US) | 2012-11-01 | — | — | US | claimed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | claimed |
| EP-2323641-A2 | NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES | Bionovo Inc. (US) | 2011-05-25 | — | — | EP | claimed |
| EP-2310024-A2 | ESTROGENIC EXTRACTS FOR USE IN TREATING VAGINAL AND VULVAR ATROPHY | Bionovo Inc. (US) | 2011-04-20 | — | — | EP | claimed |
| WO-2010120029-A1 | COMPOSITION COMPRISING THE EXTRACT OF ANEMARRHENA ASPHODELOIDES BUNGE OR THE COMPOUNDS ISOLATED FROM THE SAME FOR PREVENTING AND TREATING LIPID METABOLISM DISORDER | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2010-10-21 | — | — | WO | claimed |
| WO-2010053600-A2 | NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES | BIONOVO, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| US-20090312274-A1 | Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases | BIONOVO, INC. (US) | 2009-12-17 | — | — | US | claimed |
| US-20090304825-A1 | ESTROGENIC EXTRACTS FOR USE IN TREATING VAGINAL AND VULVAR ATROPHY | BIONOVO, INC. (US) | 2009-12-10 | — | — | US | claimed |
| WO-2009137534-A2 | ESTROGENIC EXTRACTS FOR USE IN TREATING VAGINAL AND VULVAR ATROPHY | BIONOVO, INC. (US) | 2009-11-12 | — | — | WO | claimed |
| JP-9301856-A | — | — | None | — | — | JP | disclosed |
| US-20250213593-A1 | Use of Derivatives based on Sarsasapogenin Structure and Pharmaceutical Compositions thereof | BEIJING PHYTOVENT PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| US-20250195452-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | IATERION, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4561582-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | Iaterion, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-0925598-A1 | COLOR DISPLAY DEVICE HAVING COLOR FILTER LAYERS | Koninklijke Philips Electronics N.V. (NL) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998054742-A1 | COLOR DISPLAY DEVICE HAVING COLOR FILTER LAYERS | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 1998-12-03 | — | — | WO | disclosed |
| JP-H09301856-A | ESTROGENIC AGENT | JUMOKU SEIRI KINOUSEI BUTSUSHITSU GIJUTSU KENKYU KUMIAI | 1997-11-25 | — | — | JP | disclosed |
| US-4876348-A | DEHYDROCYCLIZATION OF 2-METHYLGLUTARONITRILE, AMMOXIDATION OF REACTION MIXTURE OVER MIXED OXIDE CATALYST | THE STANDARD OIL COMPANY (US) | 1989-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312274-A1 | Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases | ESR2, ESR1, ESRRA | APP 3260/4885ESR1 2/4885ESR2 1/4885 |
| US-20120277169-A1 | NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES | ESR2, ESR1, ESRRA | APP 3260/4885ESR1 2/4885ESR2 1/4885 |
| US-20250195452-A1 | ER-BETA ESTROGENIC COMPOUNDS AND METHODS OF USE | ESR2, ESR1, ESRRB | APP 722/4885ESR1 2/4885ESR2 1/4885 |
| US-20250213593-A1 | Use of Derivatives based on Sarsasapogenin Structure and Pharmaceutical Compositions thereof | MAVS, NLN, TFAM | APP 326/4885ESR1 4720/4885ESR2 4151/4885 |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | FABP4, ACACB, LIPC | APP 698/4885ESR1 2003/4885ESR2 943/4885 |
| US-20090304825-A1 | ESTROGENIC EXTRACTS FOR USE IN TREATING VAGINAL AND VULVAR ATROPHY | CYP19A1, SHBG, ESR1 | APP 2398/4885ESR1 3/4885ESR2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.